君實生物(01877.HK)澄清未有安排配發新股或作任何討論
君實生物醫藥(01877.HK)公布,關注到有若干媒體報道,指公司將發行950萬股H股新股一事。
公司澄清,至今未就發行或配售公司新股份與任何第三方進行商討、亦無就發行或配售公司股份訂立任何協議或安排。
君實生物新冠雙抗體療法三期臨床達主要研究終點,但傳遭股東趁高配股,今早市前有一宗950萬股以每股82.12元(較昨日收市價折讓約8.8%)非自動對盤上板,涉資逾7.8億元。該股扭轉連日破頂升勢,股價曾急吐20%低見72元,半日收79.05元,急吐12%,一向薄弱成交受配股上板帶動急增至1,268萬股,涉資10.26億元;君實A股也跌逾6%曾低見84.48元人民幣。(ic-sz/k)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.